Latest revenue
—
as of —
Latest net income
—
as of —
Net margin
—
as of —
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $7.01B
- Enterprise value
- $7.01B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $36.28
- 52-wk low
- $13.79
- Beta
- —
- Shares out
- 205.3M
5-year trend
dashed bar = fiscal Q4 derived from 10-K annual − Q1 − Q2 − Q3 (SEC requires only three 10-Qs per year).
About IMVT
Business description and risk factors will appear here once IMVT's latest filing is fully ingested.
Profitability
Return on equity
-67.0%
59.6%Return on assets
-53.3%
37.0%Leverage
Debt / equity
0.26×
226.0%Debt / assets
20.4%
179.9%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q4 2025 2025-12-31 | — | — | $-110.6M | +0.4% | — |
Q3 2025 2025-09-30 | — | — | $-126.5M | -15.9% | — |
Q2 2025 2025-06-30 | — | — | $-120.6M | -38.4% | — |
Q1 2025 2025-03-31 | — | — | $-106.4M | -41.3% | — |
Q4 2024 2024-12-31 | — | — | $-111.1M | -116.1% | — |
Q3 2024 2024-09-30 | — | — | $-109.1M | -86.0% | — |
Q2 2024 2024-06-30 | — | — | $-87.2M | -17.9% | — |
Q1 2024 2024-03-31 | — | — | $-75.3M | — | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Biological Products, (No Diagnostic Substances) · SIC 2836
Your notes
Keep private notes on IMVT — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$350.0M
Insider selling
$4.0M
Net activity
+$346.0M
Distinct insiders
11
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns IMVT
Institutional value
$606.3M
Total shares held
24.6M
Distinct holders
110
-85 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 6.6M | $163.3M | +516.3K (+8.5%) | Added |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 3.7M | $92.0M | — | New |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 3.6M | $89.9M | — | New |
| 4 | JENNISON ASSOCIATES LLC | 3.2M | $79.4M | +2.5M (+356.4%) | Added |
| 5 | abrdn plc | 1.2M | $28.8M | -23.4K (-2.0%) | Trimmed |
| 6 | UBS Group AG | 684.6K | $17.0M | -47.8K (-6.5%) | Trimmed |
| 7 | Candriam S.C.A. | 680.4K | $16.9M | -680.4K (-50.0%) | Trimmed |
| 8 | VANGUARD FIDUCIARY TRUST CO | 544.5K | $13.5M | — | New |
| 9 | Connor, Clark & Lunn Investment Management Ltd. | 503.7K | $12.5M | +36.2K (+7.7%) | Added |
| 10 | Pictet Asset Management Holding SA | 472.4K | $11.7M | +91.5K (+24.0%) | Added |
| 11 | BNP PARIBAS FINANCIAL MARKETS | 334.6K | $8.3M | -18.5K (-5.2%) | Trimmed |
| 12 | Nuveen, LLC | 241.2K | $6.0M | +14.7K (+6.5%) | Added |
| 13 | Bank of New York Mellon Corp | 216.2K | $5.4M | +16.9K (+8.5%) | Added |
| 14 | Assenagon Asset Management S.A. | 205.2K | $5.1M | +0 (+0.0%) | No change |
| 15 | Swiss National Bank | 159.4K | $4.0M | +1.1K (+0.7%) | Added |
| 16 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 141.7K | $3.5M | +7.3K (+5.4%) | Added |
| 17 | Erste Asset Management GmbH | 144.5K | $3.4M | +16.0K (+12.5%) | Added |
| 18 | TD ASSET MANAGEMENT INC | 131.4K | $3.3M | -93.6K (-41.6%) | Trimmed |
| 19 | RHUMBLINE ADVISERS | 97.5K | $2.4M | +10.6K (+12.3%) | Added |
| 20 | Invesco Ltd. | 93.9K | $2.3M | +5.0K (+5.7%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once IMVT's latest filing finishes processing.